FDA Approves DIVALPROEX SODIUM — BluePoint Laboratories

# FDA Approves Generic Divalproex Sodium for BluePoint Laboratories BluePoint Laboratories has received FDA approval for its generic divalproex sodium oral formulation, expanding treatment options for patients with epilepsy, bipolar disorder, and migraine prevention while potentially increasing competitive pricing pressure in the anticonvulsant market. The approval of ANDA214643 is expected to drive market competition and improve medication accessibility as additional generic alternatives become available.